Table of Contents Table of Contents
Previous Page  924 / 1096 Next Page
Information
Show Menu
Previous Page 924 / 1096 Next Page
Page Background

S908

ESTRO 36

_______________________________________________________________________________________________

2UDepartment of Mathematical Physics and of Fluids,

Madrid, Spain

Purpose or Objective

Assessment of the differences between CT and CBCT based

dose calculation for a volumetric modulated arc therapy

(VMAT) in head and neck radiotherapy treatment.

Material and Methods

CBCT images of an Alderson RANDO phantom with tissue-

equivalent material were acquired in a Varian`s On-Board

Imager OBI (v1.5) installed on a Varian DHX accelerator,

using its standard-dose head protocol (100 kV and 2.5 slice

thickness). On the other hand, planning CT images were

acquired in a Toshiba Aquilion LB using the same phantom

and with our own clinical head and neck protocol (120 kV

and 3 mm slice thickness). Different OAR (Body, spinal

cord, parotids, mandible, oropharynx, dermis, an inner

ring with 1 cm thickness and shoulder) and a PTV were

delimitated. Additionally, reference points were inserted

over all these structures. All defined structures and points

were registered with the CBCT images by means of the

Varian rigid registration software. Both the delimitation of

volumes and the design of the treatment plan have taken

into account the limited field of view of CBCT (length 16

cm, diameter 25 cm). A head and neck VMAT plan has been

calculated in Eclipse (v10) using both sets of images. For

CT images, we only used a standard calibration curve and

3 different calibration sets of curves for CBCT images, i.e.,

standard, measured with a CATPHAN 504 phantom and

measured with a CIRS 062M head phantom placed between

head and neck RANDO slices. Dose and HU were calculated

in all reference points as well as dose-volume-histograms

for the anatomical locations for both CT and CBCT. A

gamma analysis was used for HVD comparison.

Results

The mean HU differences are less than 50 UH and the

relative dose differences are less than 3% for all the

calibration curves (Table 1) on every reference point over

all the structures.

The gamma (2%, 2 mm) DHV analysis shows an excellent

agreement for almost all the structures (>95%) (Image1).

Ring and dermis have gamma >85% .The non-pass regions

correspond to very low dose regions. The worst gamma

(>50%) corresponds to the left parotid because it is a very

small structure (10 cc) into a high gradient dose zone.

Furthermore, there is a difference of 1.8% on its volume

as measured on the CBCT and the CT images, probably due

to interpolation errors. These results are similar for all the

calibration

curves analysed.

Conclusion

CBCT images for a head and neck VMAT treatment provide

accurate dose calculation in adaptive radiotherapy,

making them suitable for the assessment of possible

changes over the original treatment planning for all the

calibration curves analyzed.

EP-1669 Assessment of the clinical value of off-line

adaptive strategies for tomotherapy treatments

D. Dumont

1

, X. Geets

2

, M. Coevoet

2

, E. Sterpin

1

1

Université catholique de Louvain, MIRO, woluwe-saint-

lambert, Belgium

2

Cliniques Universitaires Saint-Luc, radiotherapy,

woluwe-saint-lambert, Belgium

Purpose or Objective

This study assessed the clinical potential of offline

adaptive strategies based on the dose computed on daily

MVCTs (Tomotherapy). We defined clinical indicators that

were subsequently used to identify the percentage of

plans that should have been adapted due to significant

dose deviations to TVs or OARs. Only the consistency of

the initial plan throughout the treatment was addressed.

Thus, dose was reported to constants TVs and deformed

OARs.

Material and Methods

Cumulative doses were calculated from daily MVCT for 41

lung, 50 prostate and 21 H&N patients, using research

versions of off-line adaptive solutions from Accuray and

21

st

century Oncology. All deformed contours were

checked by an experienced radiation oncologist, while all

dose calculations were crosschecked using our in-house

Monte Carlo model (TomoPen). The clinical indicators